Champions Oncology (CSBR) Other Non Operating Income (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Other Non Operating Income of $39000.0 in Q1 2026, down 44.29% quarter-over-quarter from $70000.0 in Q4 2025, and up 105.26% on a YoY basis from $19000.0 in Q1 2025.
Champions Oncology (CSBR) Other Non Operating Income (2010 - 2026) Analysis & Trends
Champions Oncology's Other Non Operating Income history runs 17 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 105.26% year-over-year to $39000.0; the TTM figure through Jan 2026 stood at $227000.0 (up 102.68% YoY), while the FY2025 annual figure was $73000.0, up 52.08% from the prior year.
- Other Non Operating Income was $39000.0 for Q1 2026 at Champions Oncology, down from $70000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $81000.0 in Q2 2024 to a low of -$105000.0 in Q4 2023.
- Historically, Other Non Operating Income has averaged $13411.8 across 5 years, with a median of $14000.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income slumped 1066.67% in 2023, then surged 1400.0% in 2025.
- A 5-year view of Other Non Operating Income shows it stood at -$9000.0 in 2022, then plunged by 1066.67% to -$105000.0 in 2023, then surged by 106.67% to $7000.0 in 2024, then soared by 900.0% to $70000.0 in 2025, then sank by 44.29% to $39000.0 in 2026.
- The last three Other Non Operating Income figures came in at $39000.0 (Q1 2026), $70000.0 (Q4 2025), and $75000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 39,000.00 |
| Oct 31, 2025 | 70,000.00 |
| Jul 31, 2025 | 75,000.00 |
| Apr 30, 2025 | 43,000.00 |
| Jan 31, 2025 | 19,000.00 |
| Oct 31, 2024 | 7,000.00 |
| Jul 31, 2024 | 5,000.00 |
| Apr 30, 2024 | 81,000.00 |
| Jan 31, 2024 | 58,000.00 |
| Oct 31, 2023 | -105,000.00 |
| Jul 31, 2023 | 14,000.00 |
| Apr 30, 2023 | -20,000.00 |
| Jan 31, 2023 | 36,000.00 |
| Oct 31, 2022 | -9,000.00 |
| Jul 31, 2022 | -18,000.00 |
| Apr 30, 2022 | -35,000.00 |
| Jan 31, 2022 | -32,000.00 |
| Oct 31, 2021 | 26,000.00 |
| Jul 31, 2021 | 17,000.00 |
| Apr 30, 2021 | 7,000.00 |